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Prevention of neointimal hyperplasia associated
with modified stretch expanded
polytetrafluoroethylene hemodialysis grafts (Gore)
in an experimental preclinical study in swine
Massimiliano Gessaroli, MD, PhD,a Cristiano Bombardi, DVM, PhD,b Massimo Giunti, DVM, PhD,b
and Maria Laura Bacci, DVM, PhD,b Rimini and Bologna, Italy
Objective: Stenosis is the main cause of hemodialysis vascular graft failure and it is primarily caused by neointimal
hyperplasia (NH) development at the vein-graft anastomosis. Even thoughNHdevelopment factors are well known, their
activation pathway still remains disputed and the real role of the mismatch compliance between the vein and the graft wall
has not yet been resolved. The purpose of this experimental study in swine was to verify the possibility of preventing the
development of NH at the vein-graft anastomosis using a modified commercially available longitudinal stretch expanded
polytetrafluoroethylene (ePTFE) Gore (W. L. Gore & Associates, Flagstaff, Ariz) graft (either standard or heparin-
bonded) with an added handmade ePTFE radial stretch cuff at one end to reduce the compliance between the graft and
the vein wall.
Methods:Twelve ePTFE stretch grafts (6modified and 6 unmodified) were surgically placed as arterovenous grafts (AVGs)
between the carotid artery and the external jugular vein in 6 pigs. In each pig, one modified graft was placed on one side
and one corresponding unmodified graft on the other side as a control. In 4 pigs, standard stretch ePTFEGore grafts were
used, and in 2 pigs, heparin-bonded stretch Gore grafts were used; 2 pigs were also treated with antiplatelet drugs. All the
implanted grafts had a total length of 8 cm and a diameter of 6 mm. The modified graft was realized by cutting a short
segment of the commercially available graft lengthwise which was then sewn crosswise (rotated 90°) with the same
diameter as the original graft and was then added to it. A Doppler ultrasound scan was used for monitoring the graft
patency immediately, weekly, and before death. At death (21-28 days after implantation), artery, vein, and graft
specimens were collected “en bloc” for histopathology.
Results: The modified grafts in the antiplatelet-treated animals were able to completely prevent NH development on vein
wall (100% in 2 subjects) which was also reduced in antiplatelet untreated animals (66.5%, 96.4%, and 100% in 3 subjects,
respectively). The modified standard stretch grafts and similarly modified heparin-bonded stretch grafts obtained the
same good results in NH prevention.
Conclusion: Data provide evidence of the efficacy of modified stretch ePTFE grafts with an added radial stretch cuff for
the prevention of NH in swine models and support the hypothesis of the pivotal role of mismatch compliance between the
graft and the vein wall in NH development. (J Vasc Surg 2012;55:192-202.)
Clinical Relevance: If these results are confirmed in humans with a significantly improved graft patency, they would have
a great effect on dialysis vascular access, especially in patients with unsuitable veins for fistula creation.
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wThe low patency rate of an arteriovenous graft (AVG)
for hemodialysis has modified the impact of decision-
making by the dialysis access surgeon in favor of native
fistulas1 both in theUnited States as in Europe,2,3 although
the former are easier to create and can be used quickly. In
fact, the majority of AVGs fail due to irreversible thrombo-
sis, superimposed on hemodynamically significant vascular
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192tenoses at the site of the vein-graft anastomosis; this is
rincipally caused by the development of neointimal hyper-
lasia (NH).4 The elements which take part in the devel-
pment of NH (-smooth muscle actin positive cells de-
ived from adventitial fibroblasts, extracellular matrices, a
ariety of growth factors and neovascularization) are well
nown,5-7 but the true cause of the activation of these
omponents remains unclear and is still under debate.
ctually, NH prevention strategies (mechanical design of
he graft,8-12 biological reagents,13-15 small-molecule
rugs16) have not produced the expected results essentially
ecause they have not intervened on the initial causes.
sing synthetic vascular prostheses in AVGs, most com-
only made from expanded polytetrafluoroethylene
ePTFE), the first observation we could make was that the
ow induced vein-wall vibration at the anastomosis site17
here there was also large mismatch compliance between
he vein and the graft wall.18 As we well know, the effects of
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Volume 55, Number 1 Gessaroli et al 193cyclic strain on vascular cells, which can promote their
transformation and proliferation,19,20 and compliance mis-
match, altering suture-line stresses,21 may promote graft-
vessel NH. To lower this mismatch compliance, some
authors have proposed the use of a vein cuff22,23 at the end
of the graft but no long-term good results have been
reported. Over time, the stretch ePTFE vascular graft has
shown results equivalent to the non-stretch graft.24 These
negative results were explainable because the commercially
available stretch graft had only longitudinal stretch and not
a radial stretch similar to vessels. For this reason, we made a
compliant graft using commercially available stretch ePTFE
vascular grafts with a handmade radial stretch ePTFE cuff at
one end (pending patent: PCT/IT2010/000146), and we
undertook an experimental study in a swine model to value
the efficiency of this modification in terms of NH preven-
tion or reduction at the vein-graft anastomosis in AVGs.
The porcine model is a preclinical relevant model with a
strong translational impact and it is a valuable method for
testing different approaches which aim to study NH.25-30
METHODS
Experimental design and conduct. All experiments
were performed in compliance with European, national,
and institutional regulations on animal experimentation.
The investigation also conformed to the Guide for the Care
and Use of Laboratory Animals published by the U.S.
National Institutes of Health. Six pigs (4 males and 2
females, large white, body weight 35  3 kg) were used.
Two animals (#5 and #6) were treated for 4 days before and
10 days after surgery with salicylate (3 g/day) added to a
standard diet.
Twelve stretch ePTFE vascular grafts (6 modified and 6
unmodified) were surgically placed as AVGs between the
carotid artery and the external jugular vein. In 4 pigs (pig
#1, #2, #3, and #5), standard stretch ePTFE Gore grafts
(called G; W. L. Gore & Associates, Flagstaff, Ariz) and
modified standard stretch ePTFEGore grafts (MG) (patent
pending: PCT/IT2010/000146) were used. In 2 pigs (pig
#4 and #6), heparin-bonded stretch Gore grafts (Propaten
graft [PG]; W. L. Gore & Associates) and modified heparin-
bonded stretch Gore grafts (MPG; patent pending: PCT/
IT2010/000146) were used (Table I). In each pig, we
placed one modified and one unmodified ePTFE stretch
graft (Fig 1, A) as a control (G and MG, or PG and MPG).
All the implanted grafts had a total length of 8 cm and a
diameter of 6 mm with the same length of vein-graft
anastomosis (8 mm; Fig 1, B) and with a 45° angle between
the graft and the vein (Fig 1, C and D). The end-to-side
graft-vein anastomosis was created using 6/0 polypropyl-
ene continuous sutures in both the modified and the un-
modified graft.
The modified grafts (MG or MPG) were realized by
cutting a short segment of the commercially available
stretch graft lengthwise, which was then sewn crosswise
(rotated 90°) with the same diameter as the original graft
and was then added to it (Fig 2, A and B). hExperimental surgical procedures. The pigs, having
asted overnight with water ad libitum, were premedi-
ated with intramuscular azaperone 3 mg/kg (Stresnil;
anssen-Cilag SpA, Milan, Italy) and atropine sulfate
.02 mg/kg (Atropina Solfato; Fatro SpA, Bologna,
taly). Anesthesia was induced with 20 mg/kg ketamine
ntramuscularly (Ketavet 100; Intervet Italia Srl, Milano,
taly). An intravenous bolus of sodium thiopental (300
g/animal, Pentothal Sodium; Intervet Italia Srl) was
njected before orotracheal intubation and the pigs were
hen ventilated using a volume-controlled ventilator
ith tidal volume adjusted to maintain normocapnia
Servoventilator; Siare srl Hospital Supplies, Bologna,
taly). Anesthesia was maintained with isofluorane 1% to
.5% (Forane; Abbott Laboratories, North Chicago, Ill)
n a 1:1 mixture of oxygen and air. Antimicrobial pro-
hylaxis was carried out with enrofloxacin (2.5 mg/kg,
aytril; Bayer AG, Leverkusen, Germany) for 4 days.
In each subject, we implanted the stretch longitudinal
raft on one side (Fig 1,A and B) and, at the same time, the
orresponding modified graft with longitudinal and radial
tretch on the other side (Fig 2, A and B) as AVGs
etween the common carotid artery and the external
ugular vein. Graft patency was monitored by Doppler
ltrasound scan immediately, then weekly after surgery,
nd before death (Fig 3, A).
At the end of the experimental period (21-28 days
ostsurgery), the animals were anesthetized as previously
escribed. The neck region was exposed, and the carotid
rtery, external jugular vein, and the graft were identified
nd collected after death with an intravenous bolus of
hiopental sodium, 500 mg and 10 mL euthanasia drug
Tanax; Intervet Italia Srl).
Tissue sampling and histologic analyses. Sample
nalyses were performed by a pathologist blinded to the
reatment of each animal. The artery, the vein, and the
raft on each side were explanted en bloc (Fig 3, B) and
hen fixed in 10% formalin overnight, embedded in
araffin, and cut into serial sections, and mounted on
lass slides stained for light microscopy analysis. The
ross sections (5 m) of the graft-vein anastomosis
anastomized vein level [AVL]) and of the vein wall, 7
m distal and proximal to the graft (distal vein level
DVL] and proximal vein level [PVL]; Fig 4), were
able I. Experimental animals and treatments
Pig Gender AVG
Days
postsurgery
Salicylate
treatment
2 Male G and MG 28 dps No
3 Female G and MG 21 dps No
4 Male PG and MPG 28 dps No
5 Male G and MG 28 dps Yes
6 Female PG and MPG 21 dps Yes
VG, Arteriovenous graft; dps, disintegrations per sec; G, unmodified graft;
G, modified graft; MPG, modified Propaten graft; PG, unmodified
ropaten graft.istologically examined and compared to each other
b
p
t
(
gmen
AVG)
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January 2012194 Gessaroli et alafter staining with hematoxylin and eosin, Masson’s
trichrome stain, and elastin van Gieson and underwent
immunohistochemistry.
Immunohistochemical methods. Serial sections were
Fig 1. A, Bilateral carotid-jugular arteriovenous graft (A
and contralateral modified standard graft (MG). B, G
polytetrafluoroethylene (ePTFE) Gore graft or heparin
stretch ePTFE Gore graft or modified heparin-bonded str
of graft cut transversally, 2a: segment 2 cut longitudina
longitudinally after rotation, 4a: segment 4 sewn with se
Fig 2. A,Handmademodified Propaten graft (MPG) w
cuff at one end. B, Carotid-jugular arteriovenous graft (prepared for immunohistochemistry and, after dewaxing and tlocking of the endogenous peroxidase activity (1% H2O2 in
hosphate-buffered saline [PBS] for 30 minutes at room
emperature), underwent antigen retrieval by incubation
twice, 5 minutes each) in citrate buffer (pH 6.0). The sec-
in a pig: one side with an unmodified standard graft (G)
MG before implant. C, Standard stretch expanded
ded stretch ePTFE Gore graft. D, Modified standard
ePTFE Gore graft. 1: unmodified graft, 2: little segment
segment 2a with two oblique cuts, 4: segment 3 sewn
t 1 to obtain modified graft.
adial stretch expanded polytetrafluoroethylene (ePTFE)
with MPG in situ.VG)
and
-bon
etch
lly, 3:ith a rions were rinsed in PBS and incubated in a solution contain-
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Denver, Colo) and 0.5% Triton X-100 (Merck, Darmstadt,
Germany) in PBS for 2 hours at room temperature to block
nonspecific binding. Thereafter, the sections were incubated
in a solution containing mMAb anti--smooth-muscle actin
(1:100; 1A4; Cell Marque, Rocklin, Calif) for 24 hours at
4°C. After washing in PBS (3 times, 10 minutes each), the
sections were incubated in goat biotinylated anti-mouse (1:
200, BA-9200; Vector Laboratories, Burlingame, Calif) for 2
Fig 3. A, Postoperative Doppler ultrasound scan follo
(AVG) explanted en bloc at death.
Fig 4. Schematic diagram of external jugular vein and e
with histologic levels, sections, points of vein wall, and ne
level; DVL, distal vein level; PVL, proximal vein level.hours at room temperature, then transferred to avidin-biotin womplex (ABCkit Vectastain, PK-6100; Vector Laboratories)
or 45 minutes, and the immunoperoxidase reaction was
eveloped by 3.3’-diaminobenzidine (DAB kit, SK-4100;
ector Laboratories). The slides were dried overnight, dehy-
rated in ethanol, cleared in xylene, and coverslipped with
ntellan (Merck, Darmstaldt, Germany). The primary anti-
ody applied was diluted in a solution (1.8% NaCl in 0.01 M
BS containing 0.1% sodium azide) containing 1% normal
oat serum and 0.5% Triton-X100. The secondary antibody
. B, An example of carotid-jugular arteriovenous graft
ded polytetrafluoroethylene (ePTFE) graft anastomosis
al hyperplasia (NH) measures.AVL, Anastomized veinw-upxpan
ointimas diluted in PBS containing 1% normal goat serum and
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humid chamber.
Analysis of the sections and statistics. The sections
were observed with a Zeiss Axioplan microscope (Carl
Zeiss, Oberkochen, Germany). The images were recorded
using a Polaroid DMC digital photocamera and DMC2
software (Polaroid Corporation, Cambridge, Mass). Con-
trast and brightness images were adjusted using Adobe
Photoshop CS3 Extended 10.0 software (Adobe Systems,
San Jose, Calif). KS 300 Zeiss software (Kontron Elek-
tronik, Germany) was used for thickness analyses of vein
wall and graft wall NH (NH vein wall and NH graft wall,
respectively) and the vein wall. The vein wall and NH
thicknesses were analyzed using three nonconsecutive sec-
tions obtained at theDVL, AVL, and PVL (Fig 4). For each
section, morphometric analyses were performed on differ-
ent points (a, b, c, d, e, f); the thickness of the vein wall was
evaluated at all points on the DVL and the PVL, but only at
d, e, f points on the AVL. The NH thickness was evaluated
at all points on all levels. Data were expressed as mean 
SD. Vein wall and NH thickness were analyzed using the
t-test for each pig (G vsMG, or PG vsMPG) and for all pigs
(G plus PG vs MG plus MPG). A probability of at least P
.001 was considered significant.
RESULTS
The first pig (pig #1) was primarily used in a preliminary
experiment in order to assess the surgical procedures, to
implant the grafts, and to evaluate the explants at 25
disintegrations per second (dps). No tissue studies were
Fig 5. Histogram showing the vein wall thickness at d
[DVL], proximal vein level [PVL], anastomized vein leve
MG, modified standard graft; MPG, modified Propaten gdone on this pig. NAfter the surgical procedures, the pigs were examined
eekly with a duplex scanner to bilaterally verify the pa-
ency of the AVG; in only 1 subject was blood flow in the
nmodified AVG not able to be detected; we therefore
ecided to anesthetize this subject at 21 dps (pig #3, no
alicylate treatment).
The pigs were killed at 21 dps (pig #3 and #6) and 28
ps (pig #2, #4, and #5), respectively. The vein wall in all
igs in both sides at the proximal and distal levels did not
how any NH presence (data not shown) but only uniform
ein wall thickness due to a physiological response to blood
ow and an increase in pressure. On the contrary, in each
ig, the vein wall thickness at the AVL was significantly
igher (P .001) in the G or PG than in the MG or MPG.
he vein wall thickness of the MG or MPG at AVL was
ever significantly different from the vein wall thickness
nalyzed at the DVL and PVL in the same pig and between
igs (Fig 5).
At the AVL, the NHmeasurements are shown in Fig 6.
or pigs #2 and #3, the NH is significantly thinner (P 
001) in the modified graft, in both the graft and the vein
all. In pigs #4, #5, and #6, NH did not develop at all on
he vein wall on the side with the modified graft, also
onfirming the statistical results in these subjects (P 
001).
The same statistical analysis, carried out on pooled data
rom all animals, only with respect to the type of graft,
onfirmed that the modified graft gave excellent results
ith respect to unmodified grafts (parameters analyzed:
proximal, and anastomized vein levels (distal vein level
L]) in experimental pigs. G,Unmodified standard graft;
PG, unmodified Propaten graft. *P  .001.istal,
l [AVH and vein wall thickness, P  .001).
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NH development which was characterized by smooth mus-
cle cells and myofibroblast appearance (Fig 7). The reduc-
tion of NH development using the modified grafts (either
MG orMPG) was elevated on the vein wall as well as on the
graft wall (Table II). At the AVL in pig #4 (PG vs MPG, no
salicylate; Fig 8,A and B), pig #5 (G vs MG, salicylate; Figs
Fig 6. Histogram showing the neointimal hyperplasia (
vein wall (NHvw) and on graft wall (NHgw) in exper
standard graft; MPG, modified Propaten graft; PG, unm
Fig 7. Pig #5. Bright field photomicrographs of transverse sec-
tion (anastomized vein level [AVL], neointimal hyperplasia graft
wall [NHgw]). Note numerous -smooth-muscle actin – immu-
noreactive cells in brown. These cells correspond to smooth muscle
cells and myofibroblasts. Scale bar  100 m.8, C and D and Fig 9, A-D), and pig #6 (PG vs MPG, palicylate; Fig 8, E and F), the morphometric analyses
howed the complete or almost complete inhibition of NH
evelopment on the vein wall and the graft wall, respec-
ively, while all contralateral unmodified grafts showed
apid progression of NH.
When evaluating all cases, we did not point out the
ifferences between the use of commercially available stan-
ard and Propaten stretch Gore grafts on NH develop-
ent. All the modified grafts, either standard or Propaten,
howed almost complete inhibition of NH development in
he animals undergoing salicylate treatment and a partial
nhibition of NH in the pigs not treated with salicylate. In
ig 9, A and D, the different arrangement of PTFE fibrils
etween the standard and the modified graft (rotated 90°)
s shown, permitting the radial stretch probably reduces the
ismatch compliance between the graft and the vein wall.
The analyses of arterial anastomosis showed no evident
H development on the wall of the carotid artery or on the
raft wall at this level, bilaterally, in all subjects (data not
hown).
ISCUSSION
Stenosis at the vein-graft anastomosis mainly depends
n NH development setup by fibroblasts and smooth mus-
le cells which are derived from the local vessel wall.31 The
elease of growth factors due to surgical injury, mismatch
ompliance between the vein wall and the graft wall, oxi-
ative stress, and turbulent flow have been suggested as
thickness at anastomized vein level (AVL), measured on
al pigs. G, Unmodified standard graft; MG, modified
d Propaten graft. *P  .001.NH)
imentossible mechanisms for the activation of fibroblasts and
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January 2012198 Gessaroli et alsmooth muscle cells. Researchers have focused their efforts
on the prevention of NHby trying to block both the release
of growth factors and the transformation, proliferation,
and migration of these cells, especially with local drug
therapy16,32-34 rather than the true causes. The hypoth-
esis that the activation of these NH development factors
mainly depended on turbulent flow at the site of vessel-
graft anastomosis6,34-36 has favored the use of PTFE vas-
cular grafts with an enlarged cuff to reduce this phenome-
non. But neither the results12,37 nor the following
hemodynamic study38 have confirmed this idea. On the
contrary, with the effects of cyclic strain on vascular cells
which can promote their transformation and proliferation
being well known,19,20 some authors21 have supported the
hypothesis that compliance mismatch, altering suture-line
stress, may surely promote graft-vessel NH. In fact, suture-
line hyperplasia seems to be aggravated by the high wall
shear stress gradients noticed at the transition line from the
graft to the vein.35 For these reasons, some authors have
proposed reducing this mismatch compliance by using a
vein cuff between the graft and the vessels,22,23 but the
results were not satisfactory. In an attempt to obtain a
synthetic vascular graft with a compliance similar to the
vessels, W. L. Gore & Associates made a stretch ePTFE
Gore vascular graft but the early encouraging results be-
come equivalent to the non-stretch ePTFE graft over
time.24 These negative results probably depended on the
fact that this graft had only longitudinal stretch while the
vessel wall shows more radial stretch than longitudinal
stretch. According to this consideration and to verify the
possibility of preventing NH, we carried out an experimen-
tal study on a preclinical animal model, using a brand new
hand-made ePTFE vascular graft (patent pending: PCT/
IT2010/000146) with longitudinal and radial stretch de-
rived from the commercially available stretch ePTFE Gore
graft. For this reason, we implanted one commercially
available stretch Gore graft and one corresponding hand-
made modified Gore graft at the same time as AVG be-
tween the carotid artery and the external jugular vein in the
necks of 6 pigs, which were subsequently explanted for
histologic analysis at 21 to 28 days. The choice of these
interval times between the implant and the explant derived
from the knowledge that pigs normally show rapid and
Table II. Neointima hyperplasia reductions
Pig Gender AVG
Sal
trea
#2 Male MG vs G
#3 Female MG vs G
#4 Male MPG vs PG
#5 Female MG vs G
#6 Male MPG vs PG
AVG, Arteriovenous graft; G, unmodified standard graft; MG, modified st
unmodified Propaten graft.
Neointima hyperplasia reduction in modified graft vs unmodified ones in th
difference to 100% of the ratio of NH thickness in the modified/unmodifieaggressive NH development with AVGs25,26 and, as re- corted in the previous study, 4 weeks after the implants,
here is significant NH development but still graft pa-
ency.25,26 Although the sample of the grafts examined (5
odified grafts vs 5 unmodified grafts) might not seem
umerous, when evaluating two different grafts in the same
nimal implanted with the same technique, it is possible to
liminate interference factors due to the impossibility of
andomization in a small group of subjects. The choice of
ot giving antiplatelet drugs to some subjects also derived
rom the requirement to obtain a complete lack of interfer-
nce factors in NH development.
The results of this study provided evidence of the
fficacy of these modified stretch ePTFE grafts for
he prevention of NH in swine models. In fact, while the
mplanted ePTFE vascular graft (normally used: standard
tretch ePTFE Gore graft or Propaten stretch Gore graft)
ith only longitudinal stretch showed rapid development
f NH at the vein-graft anastomosis in all the cases consid-
red; on the contrary, in the same pigs, the corresponding
odified model of grafts with longitudinal and radial
tretch showed almost complete prevention (in pigs treated
ith salicylate) or a significant reduction (those without
alicylate treatment) of NH development. The histologic
pecimens of the cases in which salicylate was not given
howed NH developing only on the inner surface of the
uff, starting from the suture-line and completely saving
he vein wall. This could take place as a result of two
ssociated factors which occur in the days following the
VG implant. The first factor is that this modified graft
ould reduce the mismatch compliance; however, it cannot
revent platelet deposition on its inner surface near the
nastomosis without antiplatelet drugs. The second factor
s surgical injury to the intima of the vessels near the
uture-line, removing the protective endothelium and ex-
osing the smooth muscle cells.6 In these cases, the plate-
ets stick to the graft wall and the damaged endothelium
ree platelet-derived growth factors which strongly activates
he fibroblasts and the smooth muscle cells of the denuded
ntima which can migrate toward the inner surface of the
raft and proliferate. On the contrary, the same migration
oes not occur toward a vein wall with intact endothelium6
nd does not have low mismatch compliance19-21 as in our
istologic specimens. In fact, the intact endothelium se-
e
t
Reduction of NH
thickness-graft wall
Reduction of NH
thickness-vein wall
85.5% 66.5%
63.0% 96.4%
40.7% 100%
87.8% 100%
87.7% 100%
d graft; MPG, modified Propaten graft; NH, neointimal hyperplasia; PG,
e subject at graft wall and at the opposite vein wall. The percentage is the
t.icylat
tmen
No
No
No
Yes
Yes
andarretes prostacyclin PGI2 and nitric oxide which inhibit both
o
a
o
in A
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Volume 55, Number 1 Gessaroli et al 199platelet activation, aggregation, adhesion to the endothe-
lium, and also smooth muscle cell proliferation and migra-
tion.39,40 That is the probable reason as to why giving
Fig 8. A and B, Pig #4, hematoxylin and eosin stains
Neointimal hyperplasia (NH) involves both graft wall (
develops itself only on gw. C and D, Pig #5, hematoxylin
D, AVL, MG. Almost complete lack of NH developme
unmodified Propaten graft (PG). NH involves both gw
complete lack of NH development. Scale bars  500 msalicylate as an antiplatelet drug during re-endothelization af the suture-line, and then inhibiting the aggregation and
dhesion of platelets onto the modified grafts, NH devel-
pment can be completely prevented in a whole vein-graft
Anastomized vein level (AVL), unmodified graft (G).
nd vein wall (vw); B, AVL, modified graft (MG). NH
eosin stains; C, AVL, G. NH involves both gw and vw;
and F, Pig #6, hematoxylin and eosin stains; E, AVL,
vw; F, AVL, modified Propaten graft (MPG). Almost
, B, C, E, and F; 1000 m in D.; A,
gw) a
and
nt. E
andnastomosis. The aim of the antiplatelet agent in our study
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intima of the vein near the suture-line as a result of surgical
injury, and we felt that 4 days presurgery and 10 days
postsurgery was a satisfactory length of time for resolving
this problem, and that the end of the administration of the
antiplatelet agent was useful in better evaluating the real
efficacy of themodified graft. On the contrary, all vein-graft
anastomoses with unmodified grafts showed the same rapid
NH development with or without salicylate. However, the
results of this study clearly showed that a modified graft
with an added ePTFE radial stretch cuff for vein-graft
anastomosis can prevent NH in the swine model, but with
the only different factor between a modified graft vs an
unmodified graft being the radial stretch, these results also
reinforce the hypothesis of the pivotal role of mismatch
compliance in NH development.
Study limitations. Our results have unequivocally
shown that a modified graft with a radial stretch cuff
associated with salicylate can prevent NH development in
pigs at 3 to 4 weeks, but we do not know if these results
remain unchanged over time.Moreover, the swinemodel is
a valuable method for preclinically testing different ap-
proaches which aim to study NH,25-30 and it is a clinically
Fig 9. A and B, Pig #5, Masson’s trichrome stains: arran
in unmodified graft (G) with longitudinal stretch. Neoin
and D, Pig #5, Masson’s trichrome stains: new arrangem
radial stretch. NH, gw, and vw. Scale bars  200 m inrelevant preclinical model with a strong translational im- cact. Pigs actually have a more rapid and aggressive devel-
pment of NH with AVGs with respect to humans even if
he cellular phenotypes intervening in NH are similar and
hen we do not know if we can obtain these same results in
umans. It is worth noting that evaluating the progression
f NH development, flow dynamics, and different wall
ompliances between modified and unmodified grafts, and
heir relationship with vein compliance could be carried out
y ultrasound scan examination; unfortunately, in this spe-
ies, it is not possible because the implanted AVGs are very
eep, at the chest inlet, and require anesthesia. In this
tudy, using modified standard or modified Propaten
tretch grafts, we had the same results on NH inhibition at
enous-graft anastomosis but the AVG failure in hemodi-
lysis patients does not only depend on progressive stenosis
t this level (80%) and, therefore, the MPG may probably
lay an additional important role in the prevention of graft
hrombosis and in cumulative patency rates of the AVGs for
emodialysis access.
Clinical implication. The long-term survival of pa-
ients on hemodialysis is often limited by the exhaustion of
ascular access sites, but most of these depend on AVG
ailure. In fact, although AVGs are easier to create and
ent of expanded polytetrafluoroethylene (ePTFE) fibrils
hyperplasia (NH), graft wall (gw), and vein wall (vw). C
of ePTFE fibrils in modified standard graft (MG) with
d D; 500 m in B; 1000 m in C.gem
timal
entould be used quickly, rapid stenosis development at the
11
1
1
1
1
1
1
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2
2
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Volume 55, Number 1 Gessaroli et al 201vein-graft anastomosis determines a high rate of failure:
40% at 12 months. For this reason, there has been a great
push, called “Fistula First,” to promote arteriovenous fis-
tulas (AVFs) as the first line of treatment for hemodialysis
patients; this requires vascular access but not all patients
have a vein suitable for AVFs. For these patients, if modified
grafts are able to provide the same results in humans as in
our swine model, they would be preferable to AVFs.
CONCLUSION
The use of a commercially available ePTFE stretch
Gore graft modified with an added handmade radial cuff of
the same material can prevent NH development at the
vein-graft anastomosis in AVGs in the porcine model,
supporting the hypothesis of the pivotal role of mismatch
compliance between the graft and the vein wall in NH
development. These results could be better validated with
clinical and hemodynamic studies in hemodialysis patients.
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